Taiwan's HORIEN Accelerates Global Footprint: Achieves Three Thai FDA Class 4 Approvals and Secures U.S. Patent for Biodegradable Ureteral Stent

Market-entry initiative targets qualified Thai distributors across dental, surgical, wound-care, and regenerative medicine channels, while solidifying global IP leadership in advanced urological biomaterials. TAICHUNG , Sept. 8, 2026 /PRNewswire/ -- HORIEN Biochemical Technology Co., Ltd. (TPEx: 7814) today announced a major double milestone in its global expansion strategy: the formal entry into the Thai market following Thai Food and Drug Administration (Thai FDA) Class 4 approvals for three advanced regenerative medical devices, alongside securing a prestigious U.S. invention patent for its